However, the recent development of novel antibody-drug conjugates (ADCs) has significantly improved the prognosis of BC patients with low or moderate HER2 expression (1+, or 2+/ISH negative), thus leading to the concept of “HER2-low breast cancer” [7, 8]. Here, ERBB2 is linked to breast cancer.